Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab
| Autor: | Ikko, Tomisaki, Mirii, Harada, Shigeru, Sakano, Michikazu, Terado, Ryoichi, Hamasuna, Shuji, Harada, Hiroomi, Matsumoto, Soichiro, Akasaka, Yujiro, Nagata, Akinori, Minato, Ken-Ichi, Harada, Naohiro, Fujimoto |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Anticancer Research. 43:269-274 |
| ISSN: | 1791-7530 0250-7005 |
| DOI: | 10.21873/anticanres.16159 |
| Popis: | We aimed to clarify the association between body mass index (BMI) and clinical outcomes of pembrolizumab treatment for advanced urothelial cancer (UC).We retrospectively reviewed the records of patients with advanced UC who received pembrolizumab after chemotherapy between March 2018 and December 2021. Patients were divided according to BMI into the non-overweight group (BMI25 kg/mOf 84 eligible patients, 63 (75%) and 21 (25%) were in the non-overweight and overweight groups, respectively. Although the objective response rate was higher in the overweight group (55%) than that in the non-overweight group (29%), the difference was not significant. Progression-free survival (PFS) was significantly longer in the overweight group (median 15.2 months) than that in the non-overweight group (median 4.8 months; p=0.01). Overall survival was also longer in the overweight group (median 36.1 months) compared to that in the non-overweight group (13.4 months), but the difference was not significant (p=0.11). Multivariable analysis showed that overweight was significantly associated with favourable PFS. Any and severe (grade 3) irAEs were observed in 15 (24%) and 5 (7.9%) patients in the non-overweight group, respectively, and in 8 (38%) and 2 (9.5%) patients in the overweight group, respectively, but the differences were not significant.BMI was associated with oncological outcomes in patients with advanced UC who received pembrolizumab but not with the development of irAEs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|